#1 DRY EYE BRAND IN CANADA2,†
INSTANT AND ALL-DAY‡ DRY EYE RELIEF3,4
Our most advanced dry eye solution, preservative-free
*In the dry eye category in Canada.
†Nielsen MarketTrack: Tears Category, Dry Eye Segment, 5 Channel, Latest 52 weeks p.e. December 2023.
‡8 hours.
HP-guar: The key to prolonged protection and hydration retention6
HP-guar is derived from guar gum and forms a viscous solution at low concentrations7
When exposed to the pH of the tear film and ocular surface, HP-guar forms a protective viscoelastic gel matrix that:6
Prolongs retention of the ingredients to protect the ocular surface
Mimics mucins in the tear film
Reduces friction between the eyelid and the ocular surface
HP-guar preferentially binds to dried-out or damaged hydrophobic regions of the cornea, helping to limit further damage from dryness.6
Natural tears are viscous enough that they don’t evaporate too quickly, but fluid enough that they can spread to lubricate the ocular surface. HP-guar helps artificial tears mimic these properties.8
Lipid nano-droplets: Enhanced support for the tear film5
SYSTANE® COMPLETE’S nano-sized droplets contain a complex of anionic phospholipid and mineral oil4
Nano-lipid droplets fill gaps in the lipid layer and prevent tear film evaporation5,9
Lipid nano-droplets in SYSTANE® COMPLETE are formulated to provide better ocular surface coverage, promote tear film stabilization, and prolong retention of the demulcents.5
SYSTANE® COMPLETE EFFICACY IS UNPARALLELED
SYSTANE® COMPLETE Preservative-Free provides demonstrated clinical efficacy and an overwhelmingly positive patient experience3,4,10
Effective | Provides instant and all-day* symptom relief with a single drop3
For patients with moderate-to-severe discomfort, dry eye symptom scores improved immediately, and at 4 and 8 hours after administration of one drop of SYSTANE® COMPLETE3,†
*8 hours.
†Based on 45.5% of study participants, who reported moderate-to-severe symptoms at baseline (n=61)
Delivers long-term efficacy
In a prospective, randomized, multi-centre, double-masked trial, patients with dry eye disease treated their symptoms with SYSTANE® COMPLETE at least four times daily for six months.11,*
Over 70% of participants overall responded to treatment
(>4s improvement in NIBUT (p<0.05) and / or ≥4.5-point reduction on OSDI vs. baseline (p<0.01))11
Over 20% of patients treated with SYSTANE® COMPLETE no longer met the DEWS II criteria for dry eye disease after 180 days11
NIBUT = Non-Invasive Break-Up Time; OSDI = Ocular Surface Disease Index
*Signs and symptoms of dry eye were evaluated in a prospective, multicentre, double-masked, parallel group, randomized controlled trial of patients fulfilling the TFOS DEWS II diagnostic criteria for dry eye disease (n=99). Participants instilled lipid-based nanoemulsion drops or non-lipid-based aqueous drops for six months, at least four times daily. Symptomology, tear film and ocular surface characteristics were assessed at Days 0, 30, 60, 90, 120, 150 and 180.
Experience | Patients have an overwhelmingly positive experience with SYSTANE® COMPLETE10
93% rated their experience with SYSTANE® COMPLETE as good/excellent (n=254)10
98% said patient experience with SYSTANE® COMPLETE has been good/excellent (n=46)10
*Based on a US survey of Eye Care Professionals (n=46) who recruited their dry eye patients (n=254) to evaluate SYSTANE® COMPLETE after using the product for at least 4 weeks.
Ergonomic | Multi-dose bottle is designed for easier handling and less drop spillage.*
94% of ECPs said the bottle used for SYSTANE® MDPF products is easy and intuitive12
*vs. usage of unit-dose vials
Explore the rest of the
SYSTANE® portfolio
References:
1. Alcon Data on File, 2023.
2. Alcon Data on File, 2023.
3. Silverstein S, Yeu E, Tauber J, et al. Symptom Relief Following a Single Dose of Propylene Glycol-Hydroxypropyl Guar Nanoemulsion in Patients with Dry Eye Disease: A Phase IV, Multicenter Trial. Clin Ophthalmol. 2020;14:3167-3177.
4. Yeu E, et al. Efficacy and Safety of Phospholipid Nanoemulsion-Based Ocular Lubricant for the Management of Various Subtypes of Dry Eye Disease: A Phase IV, Multicenter Trial. Clin Ophthalmol. 2020;14:2561-2570.
5. Rangarajan R, Ketelson H. Pre-clinical evaluation of a novel phospholipid nanoemulsion based lubricant eye drops. Poster presented at ARVO 2017, Baltimore, MD.
6. Srinivasan S, Manoj V. A Decade of Effective Dry Eye Disease Management with Systane Ultra (Polyethylene Glycol/Propylene Glycol with Hydroxypropyl Guar) Lubricant Eye Drops. Clin Ophthalmol. 2021;15:2421-2435.
7. Petricek I, et al. Hydroxypropyl-Guar Gellable Lubricant Eye Drops for Dry Eye Treatment. Expert Opin Pharmacother. 2008;9(8):1431-1436.
8. Rangarajan R, et al. Effects of a Hyaluronic Acid/Hydroxypropyl Guar Artificial Tearnsolution on Protection, Recovery, and Lubricity in Models of Corneal Epithelium. J Ocul Pharmacol Ther. 2015;31(8):491-497.
9. Lallemand F, et al. Successfully Improving Ocular Drug Delivery Using the Cationic Nanoemulsion, Novasorb. J Drug Delivery. 2012;doi:10.115/2012/604204.
10. Alcon Data on File, 2019.
11. Craig JP, et al. Developing Evidence-Based Guidance for the Treatment of Dry Eye Disease with Artificial Tear Supplements: A Six-Month Multicentre, Double-Masked Randomised Controlled Trial. Ocul Surf. 2021;20:62-69.
Important safety information
TO BE SURE THIS PRODUCT IS RIGHT FOR YOU, ALWAYS READ AND FOLLOW THE LABEL.
